Britain’s competitors watchdog on Tuesday mentioned it was investigating the deliberate buy of US biotech firm Alexion by Covid vaccine-maker AstraZeneca in a deal value $39 billion. In a short assertion, the Competition and Markets Authority mentioned it was whether or not the deal would “lead to a considerable lessening of competitors inside any market or markets within the United Kingdom for items or companies”.
The planned tie-up, aimed at boosting AstraZeneca’s work on immunology, was announced in December as the London-listed company began to roll out the coronavirus vaccine it developed with the University of Oxford.
Read all of the Latest News, Breaking News and Coronavirus News right here
